Mechanisms of resistance to CAR-T cell immunotherapy: Insights from a mathematical model
Author:
Funder
Fundação de Amparo à Pesquisa do Estado de Minas Gerais
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Publisher
Elsevier BV
Subject
Applied Mathematics,Modeling and Simulation
Reference53 articles.
1. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma;Raje;N. Engl. J. Med.,2019
2. Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b–2, open-label study;Martin;Lancet Haematol.,2022
3. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial;Fowler;Nat. Med.,2022
4. ZUMA-3: a phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL);Shah;Ann. Oncol.,2016
5. Systematic review of available CAR-T cell trials around the world;Barros;Cancers,2022
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3